Pascolizumab
Source: Wikipedia, the free encyclopedia.
Monoclonal antibody
Humanized (from mouse) | |
|---|---|
| Target | IL-4 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
 N Y (what is this?) (verify) | |
Pascolizumab is a
humanized monoclonal antibody for the treatment of asthma.[1] A Phase II clinical trial in patients with symptomatic glucocorticoid naive asthma was conducted in 2001/2002.[2] Development was discontinued as it showed little benefit.[3]
References
- PMID 12296858.
- ^ Clinical trial number NCT00024544 for "Pilot Study in Patients With Symptomatic Steroid-Naive Asthma" at ClinicalTrials.gov
- .
| Intracellular (initiation) |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
| Unsorted |
| ||||||||||||||